<efrbr:recordSet xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:efrbr="http://vfrbr.info/efrbr/1.1" xmlns:efrbr-work="http://vfrbr.info/efrbr/1.1/work" xmlns:efrbr-expression="http://vfrbr.info/efrbr/1.1/expression" xmlns:efrbr-manifestation="http://vfrbr.info/efrbr/1.1/manifestation" xmlns:efrbr-person="http://vfrbr.info/efrbr/1.1/person" xmlns:efrbr-corporateBody="http://vfrbr.info/efrbr/1.1/corporateBody" xmlns:efrbr-concept="http://vfrbr.info/efrbr/1.1/concept" xmlns:efrbr-structure="http://vfrbr.info/efrbr/1.1/structure" xmlns:efrbr-responsible="http://vfrbr.info/efrbr/1.1/responsible" xmlns:efrbr-subject="http://vfrbr.info/efrbr/1.1/subject" xmlns:efrbr-other="http://vfrbr.info/efrbr/1.1/other" xsi:schemaLocation="http://vfrbr.info/efrbr/1.1 http://vfrbr.info/schemas/1.1/efrbr.xsd"><efrbr:entities><efrbr-work:work identifier="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0"><efrbr-work:titleOfTheWork>The effects of folinic acid and l-methylfolate supplementation on serum total homocysteine levels in healthy adults</efrbr-work:titleOfTheWork></efrbr-work:work><efrbr-expression:expression identifier="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0"><efrbr-expression:titleOfTheExpression>The effects of folinic acid and l-methylfolate supplementation on serum total homocysteine levels in healthy adults</efrbr-expression:titleOfTheExpression><efrbr-expression:formOfExpression vocabulary="DIAS:TYPES">
            Peer-Reviewed Journal Publication
            Δημοσίευση σε Περιοδικό με Κριτές
         </efrbr-expression:formOfExpression><efrbr-expression:dateOfExpression type="issued">2025-07-18</efrbr-expression:dateOfExpression><efrbr-expression:dateOfExpression type="published">2023</efrbr-expression:dateOfExpression><efrbr-expression:languageOfExpression vocabulary="iso639-1">en</efrbr-expression:languageOfExpression><efrbr-expression:summarizationOfContent>Background - Aim
Hyperhomocysteinemia is recognized as a risk factor for several diseases and conditions. The aim of this study was to investigate and compare the efficacy of two total homocysteine (tHcy)-lowering treatments including folinic acid or l-methylfolate in healthy Greek adults.
Methods
Two hundred and seventy-two healthy Greek adults (143 men, 129 women; mean age±SD: 43.0 ± 15.3 years), with serum tHcy levels ≥10 μmol/L received randomized folinic acid (“Folinic acid Group”) or l-methylfolate (“l-methylfolate Group”) orally for three months. All subjects with serum cobalamin (Cbl) levels &lt;300 pg/mL additionally received 1 mg hydroxycobalamine intramuscularly twice a week for the first month only. Serum folate, Cbl and tHcy levels were determined using immunoassays methods at the beginning and the end of the study period. The MTHFR C677T and MTHFR A1298C gene polymorphisms were genotyped using polymerase chain reaction and reverse hybridization.
Results
At the end of the 3-month intervention period, the levels of serum folate and Cbl increased significantly, whereas the levels of serum tHcy decreased significantly in the two groups. The individuals with MTHFR 677TT genotype had a significantly higher reduction in serum tHcy levels than the individuals with the MTHFR 677CC or MTHFR 677CT genotypes. Although the “Folinic acid Group” had a considerably higher increase in their serum folate levels (but not Cbl) than the “l-methylfolate Group”, the reduction of serum tHcy levels between the two groups was not substantially different. The individuals with MTHFR 677CT genotype had a statistically significant higher reduction in serum tHcy levels when supplemented with folinic acid rather than l-methylfolate.
Conclusions
The administration of folinic acid compared to l-methylfolate caused a higher increase of serum folate levels but no difference in the reduction of serum tHcy levels. The reduction of serum tHcy levels was influenced by the existence of MTHFR C677T and not MTHFR A1298C gene polymorphisms. The individuals with MTHFR 677CT genotype appear to benefit more by folinic acid than l-methylfolate supplementation.</efrbr-expression:summarizationOfContent><efrbr-expression:useRestrictionsOnTheExpression type="creative-commons">http://creativecommons.org/licenses/by/4.0/</efrbr-expression:useRestrictionsOnTheExpression><efrbr-expression:note type="journal name">Clinical Nutrition ESPEN</efrbr-expression:note><efrbr-expression:note type="journal volume">58</efrbr-expression:note><efrbr-expression:note type="page range">14-20</efrbr-expression:note></efrbr-expression:expression><efrbr-person:person identifier="C58F0462-3EC2-4696-9E35-5DA3BE154297"><efrbr-person:nameOfPerson vocabulary="">
            Mazokopakis Elias
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="http://users.isc.tuc.gr/~mpapadomanolaki"><efrbr-person:nameOfPerson vocabulary="TUC:LDAP">
            Papadomanolaki Maria
            Παπαδομανωλακη Μαρια
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-person:person identifier="5A9414DA-AC69-4E8B-8C86-7CA2122AF5C9"><efrbr-person:nameOfPerson vocabulary="">
            Papadakis John
         </efrbr-person:nameOfPerson></efrbr-person:person><efrbr-corporateBody:corporateBody identifier="https://v2.sherpa.ac.uk/id/publisher/30"><efrbr-corporateBody:nameOfTheCorporateBody vocabulary="S/R:PUBLISHERS">
            Elsevier
         </efrbr-corporateBody:nameOfTheCorporateBody></efrbr-corporateBody:corporateBody><efrbr-concept:concept identifier="270BB4A7-8D61-49CD-BBD2-E59A883E8339"><efrbr-concept:termForTheConcept>
            Cobalamin
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="6AF2477D-7245-4CE9-A7E4-F1999B90E2BC"><efrbr-concept:termForTheConcept>
            Folinic acid
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="84FB095E-1139-442F-9047-35414593E776"><efrbr-concept:termForTheConcept>
            Homocysteine
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="2C63D294-F53E-4C75-8249-84EB5A558E5D"><efrbr-concept:termForTheConcept>
            L-methylfolate
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="3E7D8070-9698-438D-B2AD-22929DD4FF47"><efrbr-concept:termForTheConcept>
            MTHFR C677T
         </efrbr-concept:termForTheConcept></efrbr-concept:concept><efrbr-concept:concept identifier="879915A8-BCEE-4B57-AEA1-DA80531FC992"><efrbr-concept:termForTheConcept>
            MTHFR A1298C
         </efrbr-concept:termForTheConcept></efrbr-concept:concept></efrbr:entities><efrbr:relationships><efrbr-structure:structureRelations><efrbr-structure:realizedThrough sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="expression" targetURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0"/></efrbr-structure:structureRelations><efrbr-responsible:responsibleRelations><efrbr-responsible:createdBy sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="person" targetURI="C58F0462-3EC2-4696-9E35-5DA3BE154297"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="person" targetURI="C58F0462-3EC2-4696-9E35-5DA3BE154297" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="person" targetURI="http://users.isc.tuc.gr/~mpapadomanolaki" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="person" targetURI="5A9414DA-AC69-4E8B-8C86-7CA2122AF5C9" role="author"/><efrbr-responsible:realizedBy sourceEntity="expression" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="person" targetURI="https://v2.sherpa.ac.uk/id/publisher/30" role="publisher"/></efrbr-responsible:responsibleRelations><efrbr-subject:subjectRelations><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="270BB4A7-8D61-49CD-BBD2-E59A883E8339"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="6AF2477D-7245-4CE9-A7E4-F1999B90E2BC"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="84FB095E-1139-442F-9047-35414593E776"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="2C63D294-F53E-4C75-8249-84EB5A558E5D"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="3E7D8070-9698-438D-B2AD-22929DD4FF47"/><efrbr-subject:hasSubject sourceEntity="work" sourceURI="http://purl.tuc.gr/dl/dias/FD53945C-0691-411E-AB9A-5FBF15337FE0" targetEntity="concept" targetURI="879915A8-BCEE-4B57-AEA1-DA80531FC992"/></efrbr-subject:subjectRelations><efrbr-other:otherRelations/></efrbr:relationships></efrbr:recordSet>